The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of…
Articles by Inês Martins, PhD
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to…
Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose…
With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to…
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and…
Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory…
The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients…
A three-drug combination that includes thalidomide, in place of cyclophosphamide, prior to an autologous stem cell transplant was seen to improve response…
The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with …
A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show…